Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Emapalumab for the Prevention of CAR-T Cell Associated Toxicities

NCT06550141 is registered in ClinicalTrials.gov with Marcela V. Maus, M.D.,Ph.D. as lead sponsor.

NCT NCT06550141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06550141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Emapalumab for the Prevention of CAR-T Cell Associated Toxicities
Lead sponsor
Marcela V. Maus, M.D.,Ph.D.
Phase
Phase 2
Overall status
Recruiting
Start date
September 18, 2024
Completion date
August 1, 2028
Enrollment
28 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, follicular lymphoma, high-grade b-cell lymphoma, large b-cell lymphoma, primary mediastinal large b-cell lymphoma, refractory non-hodgkin lymphoma, relapsed non-hodgkin lymphoma